Fig. 1 · Structure

Documents & Downloads

GSK461364

Cat. No. A10442 CAS 929095-18-1

PLK Inhibitor

GSK461364 is an ATP-competitive inhibitor of polo-like kinase 1 (Plk1).

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

GSK461364 targets the ATP-binding pocket of PLK1. A co-crystal with a surface-mutated PLK1 kinase domain places the inhibitor at the hinge near Cys133. In a separate wild-type kinase-domain activity assay at 10 mM ATP, its IC50 was 2.5 nM (n = 1). These results establish binding-site and assay-specific activity; the IC50 is not a treatment dose. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
PLK1 (Cell-free assay) Ki 2.2 nM

Cellular Effect

Cell Line Activity Value Description Reference
HEK-293T IC50 1 nM Antiproliferative activity against HEK293T cells measured after 72 hrs by CellTiter-Blue assay [PMID: 28792760]
MDA-MB-231 IC50 1 nM Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by CellTiter-Blue assay [PMID: 28792760]
MM1.S IC50 1 nM Antiproliferative activity against human MM1S cells measured after 72 hrs by CellTiter-Blue assay [PMID: 28792760]
MV4-11 GI50 0.679 μM Cytotoxicity against human MV4-11 cells after 24 hrs by CellTiter-Blue assay [PMID: 26191363]

GSK461364 Research Summary

This section summarizes 4 in vitro studies and 1 in vivo study of GSK461364 from 4 published references. In vitro models include recombinant human wild-type PLK1 kinase domain, residues 33–345.

GSK461364 In Vitro Studies

In a 72-hour MTT assay, GSK461364 gave GI50 values of 10 ± 1.5 nM in SK-N-AS and 13 ± 4 nM in IMR32 neuroblastoma cells. Sensitivity varied across the six-cell-line panel, with SH-SY5Y less sensitive than these two models. The viability endpoint alone does not establish apoptosis. [2]

Cellular responses depend on context. In HCT116 cells treated with 20 nM GSK461364 for 8 h, centrosome-separation failure occurred in 16% of p53-competent mitotic cells and >60% of p53-null cells. This is evidence for a p53-associated difference in this isogenic model. [3]

PLK1 kinase activity under high-ATP conditions

Biochemical assay · Recombinant human wild-type PLK1 kinase domain, residues 33–345 [1]

GSK461364 inhibited peptide phosphorylation with an IC50 of 2.5 nM at 10 mM ATP. Table 4 reports n = 1; this is an assay IC50, not a binding constant or treatment dose.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of PLK1-dependent substrate phosphorylation at 10 mM ATPIC50 2.5 nM (n = 1)[1]

Literature-Reported Treatment Conditions

Treatment concentration
11 concentrations from 20 µM to 0.1 nM; duplicate wells per concentration
Exposure duration
15 min pre-binding; 30 min kinase reaction at 22°C
Method
TR-FRET peptide-phosphorylation assay; four-parameter IC50 fit
Vehicle
DMSO; test compounds added as 100-fold concentrated DMSO solutions
Reported limits
Table 4 gives n = 1 without uncertainty for GSK461364. Normalization control definitions are not stated in Section 2.3.
Methods and source locations

Compound reported in the paper: GSK461364

Evidence for the named research compound in this reported material and model; no Adooq lot, formulation equivalence or clinical efficacy validation.

Section 2.3; Table 4, GSK461364 row; Section 3.2

Inhibition of PLK1-dependent substrate phosphorylation at 10 mM ATP: TR-FRET; duplicate concentrations; n = 1 as printed in Table 4 is distinct from technical duplicate wells. — Section 2.3; Table 4, GSK461364 row

GSK461364 binding in a PLK1 co-crystal

Biochemical assay · Human PLK1 kinase domain residues 18–340 with K225D/K226A surface mutations; PDB 9r1y [1]

The co-crystal places GSK461364 in the ATP-binding pocket, with an imidazole nitrogen hydrogen-bonded to the Cys133 backbone amide. The structure uses a surface-mutated kinase domain.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Diffraction resolution for PLK1 K225D/K226A:GSK461364Resolution 2.60 Å[1]

Literature-Reported Treatment Conditions

Treatment concentration
2 mM ligand for co-crystallization
Exposure duration
1–2 h ligand preincubation at 277 K; crystal growth at 293 K
Method
X-ray co-crystallography of the K225D/K226A kinase domain
Vehicle
Ligand stock in DMSO
Reported limits
No unmodified full-length PLK1–GSK461364 co-crystal comparison is reported here; no new selectivity panel is inferred.
Methods and source locations

Compound reported in the paper: GSK461364

Evidence for the named research compound in this reported material and model; no Adooq lot, formulation equivalence or clinical efficacy validation.

Sections 2.2, 2.4, 3.1 and 3.2.3; Figure 1d; Figure 6; Tables 2–3, GSK461364 column

Diffraction resolution for PLK1 K225D/K226A:GSK461364: X-ray diffraction; Table 2 range 42.43–2.60 Å. — Table 2, PLK1 K225D/K226A:GSK461364 column; Figure 6

GSK461364 response in a neuroblastoma viability panel

Cell-based study · Human SK-N-AS, SH-SY5Y, SH-EP, IMR32, Kelly and SK-N-BE neuroblastoma cells, spanning MYCN single-copy/amplified and TP53 wild-type/mutant backgrounds [2]

Sensitivity varied across this 72-hour MTT panel. Exact Figure 1B GI50 labels are 10 ± 1.5 nM for SK-N-AS and 13 ± 4 nM for IMR32. SH-SY5Y is less sensitive by the higher bar in Figure 1A. The viability endpoint does not alone establish cell death or universal biomarker independence.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MTT-based viability inhibition in SK-N-AS after 72 hGI50 10 ± 1.5 nM[2]
MTT-based viability inhibition in IMR32 after 72 hGI50 13 ± 4 nM[2]
Relative MTT GI50 across the neuroblastoma panelQualitative cell-line comparison SH-SY5Y has a higher GI50 bar than SK-N-AS and IMR32[2]

Literature-Reported Treatment Conditions

Treatment concentration
0.01–1000 nM
Exposure duration
72 h
Method
MTT assay, relative to solvent-treated cultures
Vehicle
Matched DMSO carrier control
Reported limits
Exact number of biological experiments for these displayed fits is not separately given; general Methods state at least three independent experiments in triplicate. ± follows the figure labels; Statistics identifies error bars as SD.
Methods and source locations

Compound reported in the paper: GSK461364

Evidence for the named research compound in this reported material and model; no Adooq lot, formulation equivalence or clinical efficacy validation.

Results first subsection; Figure 1A–B/caption; Methods: Compound, Cell assays, Statistics

MTT-based viability inhibition in SK-N-AS after 72 h: Exact annotation in Figure 1B; not digitized from curve. General Statistics: SD. — Figure 1B, SK-N-AS GI50 annotation; Figure 1 caption; Statistics

MTT-based viability inhibition in IMR32 after 72 h: Exact annotation in Figure 1B; not digitized from curve. General Statistics: SD. — Figure 1B, IMR-32 GI50 annotation; Figure 1 caption; Statistics

Relative MTT GI50 across the neuroblastoma panel: Visual comparison of original Figure 1A; no exact bar-derived value reported. The Results all-lines <20 nM statement conflicts with the SH-SY5Y bar and is not adopted. — Figure 1A and Results first subsection

p53-dependent centrosome response to PLK1 inhibition

Cell-based study · Parental HCT116 p53+/+ and isogenic p53−/− human colorectal carcinoma cells [3]

After 20 nM GSK461364 for 8 h, centrosome-separation failure was more frequent in p53-null cells. Untreated cells of both genotypes showed little failure. This is a model-specific response, not a universal p53 sensitivity rule.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Mitotic cells failing centrosome separation after GSK461364Percentage p53+/+: 16%; p53−/−: >60%[3]

Literature-Reported Treatment Conditions

Treatment concentration
20 nM
Exposure duration
8 h
Method
γ-Tubulin immunofluorescence; mitotic cells identified by DAPI; >100 cells per condition, scored by two individuals
Vehicle
DMSO control in caption; plotted controls labeled untreated
Reported limits
DMSO concentration not specified for Figure 7B. Representative of two independent experiments; caption calls error bars the standard deviation of the mean.
Methods and source locations

Compound reported in the paper: GSK461364

Evidence for the named research compound in this reported material and model; no Adooq lot, formulation equivalence or clinical efficacy validation.

Results: p53 protects cells from PLK1 inhibition by maintaining centrosome separation; Figure 7B/caption; Cell culture; Antibodies and reagent; Immunofluorescence

Mitotic cells failing centrosome separation after GSK461364: Values are reported in Results, corroborated qualitatively by viewed Figure 7B; no exact graph-derived decimals. — Results, paragraph beginning PLK1 is a major upstream component; Figure 7B/caption

GSK461364 In Vivo Studies

GSK461364A suppressed growth of T4888M anaplastic thyroid carcinoma allografts in immunocompetent mice at 50 mg/kg intraperitoneally every other day for six doses. The study also reported an average 7% body-weight loss after one week and lower neutrophil counts than vehicle controls. Tumor growth increased after the dosing period. [4]

Tumor growth and adverse findings in an ATC allograft model

Animal study · T4888M mouse ATC cells derived from a lung metastasis of a thyroid-specific Pten/p53 knockout mouse, allografted into immunocompetent female 129Sv mice [4]

GSK461364A suppressed allograft growth during a six-dose alternate-day course. The same experiment reported body-weight loss and reduced neutrophil counts; it does not establish systemic safety or clinical efficacy.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Body-weight loss after one week of GSK461364A treatmentAverage body-weight loss 7%[4]
Peripheral neutrophil counts in treated versus control miceNeutrophil count GSK461364A: 1.87 × 10³/µL; control: 5.94 × 10³/µL[4]

Conditions shared by the study groups

Route
Intraperitoneal injection
Frequency
Every other day
Treatment course
Six administrations (q2dx6)
Vehicle
2% Cremophor EL, 2% N,N-dimethylacetamide in acidified water (pH 5)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
GSK461364A versus vehicle
50 mg/kg
Randomized vehicle group; treatment began at 100–250 mm³ tumor volumeTumor growth was suppressed relative to vehicle; growth resumed/increased after the dosing period in the viewed Figure 7. Average body-weight loss was 7% after one week. Neutrophils were lower in treated animals (1.87 × 10³/µL) than controls (5.94 × 10³/µL).[4]
GSK461364A versus vehicle
Model: T4888M ATC allografts in female wild-type 129Sv mice, 8–10 weeks old; n = 16 total
Reported limits: Group-specific n, figure error-bar definition and a numerical tumor-growth inhibition percentage are not specified in the retrieved text/caption. No exact tumor volumes are extracted from the curve.
Methods and source locations

Compound reported in the paper: GSK461364A

Evidence for the named research compound in this reported material and model; no Adooq lot, formulation equivalence or clinical efficacy validation.

Methods: In vivo model; Results paragraphs before/after Figure 7; Figure 7/caption

Body-weight loss after one week of GSK461364A treatment: Reported in Results; dispersion and group-specific n not given. — Results, animal efficacy paragraph before Figure 7

Peripheral neutrophil counts in treated versus control mice: Forcyte blood count analyzer; Results note leukocytosis and treated count within cited normal range. Timing and dispersion not specified for these values. — Methods: In vivo model; Results paragraph after Figure 7

GSK461364A versus vehicle · Methods: In vivo model; Results paragraphs before/after Figure 7; Figure 7/caption

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 929095-18-1
Applications PLK Inhibitor
Formula C27H28F3N5O2S
Molecular Weight 543.6
SMILES
C[C@H](C1=CC=CC=C1C(F)(F)F)OC2=C(SC(=C2)N3C=NC4=C3C=C(C=C4)CN5CCN(CC5)C)C(=O)N

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 9 mg/mL (16.55 mM)
Water Insoluble
Ethanol 27 mg/mL (49.66 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
1% DMSO+30% polyethylene glycol+1% Tween 80

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

GSK461364 Research References

  1. [1] Eberspaecher U, Schmitz AA, Siemeister G, et al. Polo-like kinase 1-inhibitor co-complex structures via the surface-entropy reduction approach and a DARPin-assisted approach Acta crystallographica. Section D, Structural biology (2025). PMID: 41246821 DOI: 10.1107/s2059798325009325 Source material
  2. [2] Pajtler KW, Sadowski N, Ackermann S, et al. The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models Oncotarget (2017). PMID: 28036269 DOI: 10.18632/oncotarget.14268 Source material
  3. [3] Smith L, Farzan R, Ali S, et al. The responses of cancer cells to PLK1 inhibitors reveal a novel protective role for p53 in maintaining centrosome separation Scientific reports (2017). PMID: 29170437 DOI: 10.1038/s41598-017-16394-2 Source material
  4. [4] Russo MA, Kang KS, Di Cristofano A. The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations Thyroid : official journal of the American Thyroid Association (2013). PMID: 23509868 DOI: 10.1089/thy.2013.0037 Source material

Added to your cart

View Cart Checkout
Loading...